Headlines about Radius Health (NASDAQ:RDUS) have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Radius Health earned a coverage optimism score of 0.17 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 45.6282495552361 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
These are some of the headlines that may have effected Accern’s scoring:
- Radius Health Presents Positive Data for TYMLOSâ„¢ (abaloparatide) Injection from the ACTIVExtend Trial at ASBMR … – GuruFocus.com (gurufocus.com)
- Radius Health Presents Positive Data for TYMLOS™ (abaloparatide) Injection from the ACTIVExtend Trial at ASBMR … – GlobeNewswire (press release) (globenewswire.com)
- Insider Buying: Radius Health, Inc. (RDUS) Major Shareholder Acquires 50,000 Shares of Stock (americanbankingnews.com)
- Radius Health to Present at Morgan Stanley 15th Annual Global Healthcare Conference (finance.yahoo.com)
- Radius Health (RDUS) Down 12.7% Since Earnings Report: Can It Rebound? (finance.yahoo.com)
Shares of Radius Health (NASDAQ:RDUS) traded down 0.96% on Monday, reaching $36.25. 290,590 shares of the company’s stock traded hands. The firm’s market capitalization is $1.58 billion. The company’s 50-day moving average is $38.40 and its 200-day moving average is $39.37. Radius Health has a 52 week low of $31.58 and a 52 week high of $59.22.
Radius Health (NASDAQ:RDUS) last announced its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($1.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.35) by $0.23. The company had revenue of $0.98 million for the quarter, compared to analyst estimates of $1.96 million. During the same quarter last year, the company earned ($1.01) EPS. Equities research analysts anticipate that Radius Health will post ($5.58) earnings per share for the current fiscal year.
A number of equities analysts have recently commented on RDUS shares. Jefferies Group LLC set a $34.00 target price on shares of Radius Health and gave the company a “hold” rating in a research note on Monday, June 5th. ValuEngine raised shares of Radius Health from a “sell” rating to a “hold” rating in a research note on Thursday, June 22nd. BidaskClub raised shares of Radius Health from a “hold” rating to a “buy” rating in a research note on Tuesday, June 27th. Zacks Investment Research raised shares of Radius Health from a “sell” rating to a “hold” rating in a research note on Tuesday, August 8th. Finally, Cantor Fitzgerald set a $65.00 target price on shares of Radius Health and gave the company a “buy” rating in a research note on Monday, May 22nd. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and four have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $53.60.
WARNING: This article was published by Markets Daily and is the property of of Markets Daily. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States & international copyright legislation. The original version of this article can be read at https://www.themarketsdaily.com/2017/09/11/radius-health-rdus-getting-somewhat-favorable-news-coverage-accern-reports.html.
In related news, major shareholder Growth N. V. Biotech bought 60,000 shares of the company’s stock in a transaction on Wednesday, August 16th. The shares were purchased at an average cost of $35.98 per share, for a total transaction of $2,158,800.00. Following the acquisition, the insider now owns 5,248,799 shares of the company’s stock, valued at approximately $188,851,788.02. The purchase was disclosed in a filing with the SEC, which is available at this link. Also, major shareholder Growth N. V. Biotech bought 150,000 shares of the company’s stock in a transaction on Thursday, August 10th. The shares were bought at an average price of $34.97 per share, for a total transaction of $5,245,500.00. Following the completion of the acquisition, the insider now directly owns 5,113,799 shares in the company, valued at approximately $178,829,551.03. The disclosure for this purchase can be found here. Insiders have acquired a total of 260,000 shares of company stock worth $9,241,800 over the last 90 days. Corporate insiders own 15.00% of the company’s stock.
Radius Health Company Profile
Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Receive News & Ratings for Radius Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.